HEALTH TECHNOLOGY

Nanomix Enters into Distribution Agreement for the eLab System and Future New Products with BIOASIA PTE LTD in Singapore

Nanomix Corporation and BIOASIA PTE LTD. | August 24, 2022 | Read time : 03:00 min

Nanomix Enters

Nanomix Corporation a leader in the development of mobile, affordable, point-of-care diagnostics,  announced that it has entered into a distribution agreement with BIOASIA PTE LTD a medical diagnostics distributor located in Singapore. Bioasia will market and distribute the Nanōmix eLab® system in Singapore and Brunei, including the Nanōmix S1 Panel assay and future new test products for the eLab system.

We are pleased to introduce and give access to much needed, new diagnostics to our hospitals and customers.  Sepsis and critical infections are a challenge in Singapore in the same way they are around the world.  Our partnership with Nanomix will help us bring a unique option to our customers and the healthcare system in Singapore.”

Henry Lim, Managing Director of Bioasia

Thomas Schlumpberger, Chief Executive Officer of Nanomix, stated, “Nanomix is at the cusp of commercialization and continues to show early successes in executing upon our commercialization strategy.  We are excited to see increased interest in our products especially in Asia, beginning in Singapore, which represents a significant and untapped growth opportunity for Nanomix.”

John Hardesky, Chief Commercial Officer of Nanomix, stated, “Singapore has been ranked as one of the most efficient healthcare systems in the world for many years. The Nanōmix eLab® analyzer runs the S1 Panel assay rapidly, diagnosing critical infections including sepsis in 12 minutes which will undoubtedly lead to breakthroughs in earlier sepsis patient diagnosis.”

Sepsis is a recognized global health crisis. Early identification and treatment are a need and a challenge for healthcare professionals around the globe. For many reasons, sepsis can be difficult to identify and is frequently under-diagnosed in the earliest stages. It affects as many as 50 million people every year, leading to approximately 11 million deaths annually.

The Nanōmix eLab® system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing. The Nanōmix eLab® system offers a variety of benefits, including results in minutes, lower cost, and portability, while providing accurate, quantitative results comparable in quality to those provided by central lab testing. Furthermore, the S1 Panel Cartridge was developed as an aid in rapidly diagnosing critical infections including sepsis. The panel provides quantitative test results for procalcitonin (PCT), C-reactive protein (CRP) and lactate (LAC) from a single venous whole blood or plasma sample type. The assay runs on the eLab® Analyzer with results available in approximately 12 minutes from sample to answer, versus the current diagnostic solutions which can take hours to provide a test result. The S1 Panel assay has received the CE marking in Europe and has UK Medicines and Healthcare products Regulatory Agency (MHRA) registration.

About BIOASIA PTE LTD
Bioasia was established in 2005 focusing on medical marketing and distribution of critical care products and monitoring equipment for patients requiring intensive care in intensive care settings.  Our staff are professional biomedical engineers with knowledge of ISO13485.  We work with medical professionals in hospital settings to ensure in-hospital equipment are at optimal working conditions for effective patient monitoring and results. Bioasia has represented various medical device companies in Singapore and Brunei markets since 2005. Bioasia is GDPMDS certified.

About Nanomix Corporation
Nanomix is developing mobile point-of-care diagnostics with its Nanōmix eLab® System platform and assays that provide rapid, accurate, quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The company’s products are designed to broadly impact healthcare delivery by bringing diagnostics to the point of initial patient interaction, whether in the hospital or in pre-hospital, remote or alternate-care settings, thereby enabling faster clinical decision-making and potentially treatment-in-place. Nanomix’s first assays address the need for faster diagnosis of critical infections including sepsis. The company is developing a pipeline of other tests designed to improve patient outcomes by making high-quality diagnostic information available within minutes. 

Spotlight

Long a part of the backwaters of antitrust enforcement, vertical mergers have recently attracted the attention of academics and enforcers. The Federal Trade Commission’s hearings on vertical merger policy and the issue of whether to publish new Vertical Merger Guidelines,2 along with recent cases including the Department’s unsuccessful challenge to AT&T’s acquisition of Time Warner3 and speeches by enforcement officials4 illustrate a renewed focus on vertical combinations. It is widely recognized that the Department of Justice Non-Horizontal Merger Guidelines are out of date and do not reflect modern economic thinking or government enforcement policy. Indeed, a large body of theoretical and empirical work has served to undermine the economic foundations of the laissez-faire approach that has characterized government policies over the last thirty years.

Spotlight

Long a part of the backwaters of antitrust enforcement, vertical mergers have recently attracted the attention of academics and enforcers. The Federal Trade Commission’s hearings on vertical merger policy and the issue of whether to publish new Vertical Merger Guidelines,2 along with recent cases including the Department’s unsuccessful challenge to AT&T’s acquisition of Time Warner3 and speeches by enforcement officials4 illustrate a renewed focus on vertical combinations. It is widely recognized that the Department of Justice Non-Horizontal Merger Guidelines are out of date and do not reflect modern economic thinking or government enforcement policy. Indeed, a large body of theoretical and empirical work has served to undermine the economic foundations of the laissez-faire approach that has characterized government policies over the last thirty years.

Related News

HEALTHTECH SECURITY

KORU Medical Systems Appoints Brent Rutland as Vice President of Medical Affairs

KORU Medical | October 13, 2022

KORU Medical Systems, Inc. a leading medical technology company focused on the development of innovative and easy-to-use subcutaneous infusion solutions announced the appointment of Brent Rutland as the Company’s new Vice President of Medical Affairs. Mr. Rutland will provide leadership in the Company’s clinical and data generation strategies, key opinion leader engagement, assessing new subcutaneous drug candidates for use with the Company’s products and overseeing the medical affairs team. Additionally, Mr. Rutland will be the clinical resource for the Company’s efforts in regulatory submissions, failure modes and effects analysis, health hazard evaluations, human factors design, new product development and clinical evaluation updates. “We are excited to bring Brent’s competence to the organization – his background was a perfect fit. His expertise will advance clinical evidence generation in support of our product pipeline, provide valuable insight to our drug therapy candidates and help develop important key opinion leader relationships. Brent has helped build multiple data and clinical strategies, internal teams, and external networks in his past. His deep industry experience and passion for the patient, will make him an impactful contributor to the Company’s strategy.” Linda Tharby, President and CEO Mr. Rutland’s career history spans an impressive 27 years and includes working with Baxter Healthcare as a Senior Medical Science Liaison and most recently with La Jolla Pharmaceutical Company as a Senior Director, Health Outcomes. During his career he helped launch 7 vaccines, 4 drugs and 1 device. Most notably, Brent aided Baxter in the launch of Hylenex for SQ rehydration where he also helped build the Medical Affairs department. He has received several awards throughout his career, with the most recent being the President’s Circle Award for Medical Affairs at La Jolla. Brent holds a Bachelor of Science degree from Texas A&M University, an MBA in Global Management from the University of Houston, and his Master of Public Health from the University of North Carolina in Epidemiology. “I was immediately drawn to the opportunity to work at KORU Medical as I saw the potential for future growth supported by building out the medical science and the team,” said Brent Rutland, Vice President of Medical Affairs. “Medical affairs helps fulfill the unmet needs of the patient through the generation and delivery of scientific evidence to various key outside stakeholders. I look forward to developing a collaborative strategy to support the Company’s overall goals.” About KORU Medical KORU Medical develops, manufactures, and commercializes innovative and easy-to-use subcutaneous infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System. currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in the home and alternate care settings.

Read More

HEALTH TECHNOLOGY

FDA-approved Investigator-initiated Pre-market Clinical Trial of LAmbre™ Plus LAA Closure System Obtained Medical Insurance Coverage in the US

LifeTech Scientific Corporation | September 06, 2022

LifeTech Scientific Corporation is pleased to announce that on 30 August 2022, an FDA-approved investigator-initiated pre-market clinical trial of its proprietary LAmbre™ Plus Left Atrial Appendage (LAA) Closure System has obtained medical insurance coverage in the United States, meaning that all patient enrollment of the clinical trial will be fully covered by the USA medical insurance. This is expected to facilitate the marketing and registration process of the innovative device in the United States and provide strong clinical data to support the development of the device in the global market. The investigator-initiated pre-market clinical trial received FDA approval in March 2022. This prospective, randomized, controlled, multicenter clinical trial aims to evaluate the safety and efficacy of the implantation of LAmbre™ Plus LAA occluder in non-valvular atrial fibrillation patients with large and/or irregularly shaped appendages, as compared to oral anticoagulants. The trial is planning to enroll more than 3,000 subjects from up to 75 investigational sites in the United States and undertake more than 1,500 implantations of the LAmbre™ Plus LAA occluders at a fee. After reaching the established clinical objectives and conditions, the company will submit the marketing application of the device to the FDA. "This is a great milestone in LifeTech's international roadmap. Our LAA occluders had been successfully implanted in the United States on a basis of 'compassionate use', providing a new treatment for non-valvular atrial fibrillation patients with irregularly shaped appendages. Today, the approval for the first ever USA based investigator-initiated pre-market clinical trial and the medical insurance coverage gives us a greater confidence to further accelerate our process for providing this innovative, safe and effective stroke prevention solution to patients in the United States," Mr. Xie Yuehui, Chairman and CEO, LifeTech Scientific Corporation About the LAmbre™ Plus LAA Closure System LAmbre™ Plus LAA Closure System is independently developed by LifeTech Scientific Corporation. The device closes patient's left atrial appendage through percutaneous occlusion procedure to prevent stroke caused by detachment of thrombus from the left atrial appendage. LAmbre™ Plus LAA Closure System is a structural optimized version of the LAmbre™ LAA Closure System, which is an advanced medical device in the industry in terms of design and technology, and currently it has been widely used in over 40 countries with nearly 20,000 cases in clinical application around the world. About LifeTech Scientific Corporation Established in 1999, LifeTech Scientific Corporation (1302.HK) is committed to the R&D, manufacture, and sales of minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases. The company has a comprehensive product portfolio in the treatment of structural heart diseases, peripheral vascular diseases, bradycardia, neurological, neoplastic and respiratory diseases, alongside a unique iron-based bioresorbable technology. To date, 14 of the company's products have been approved as innovative medical devices by the National Medical Products Administration, and with a global reach of over 100 countries and regions, the company is currently one of the few domestic companies in China with a highly internationalized business structure.

Read More

HEALTH TECHNOLOGY

Stryker Launches Q Guidance System with Spine Guidance Software

Stryker | September 28, 2022

Stryker one of the world’s leading medical technology companies, announced the launch of its Q Guidance System for spine applications. The System combines new optical tracking options provided by a redesigned, state-of-the-art camera with sophisticated algorithms of the newly launched Spine Guidance Software to deliver more surgical planning and navigation capability than ever before. When used with the Q Guidance System, the Spine Guidance Software is intended as a planning and intraoperative guidance system to enable open or percutaneous computer-assisted surgery and is the first spine navigation software to receive FDA clearance for use with pediatric patients aged 13 and older. “The Q Guidance System offers cutting-edge tracking options with its 4th generation FP8000 camera, and Spine Guidance Software allows for advanced planning and computer-assisted execution. With the addition of the Q Guidance System, customers now have access to a robust solution that includes imaging, guidance, and instruments and is fully integrated and designed to meet complex customer needs. In the years to come, our goal is to use the versatility of this System to help advance our technologies across multiple specialties including cranial, spine, ENT, and orthopaedics.” Robbie Robinson, President of the Spine division Q Guidance offers surgeons numerous benefits, including A proprietary camera: The Q Guidance System features a 4th generation FP8000 camera that offers unmatched speeds and the flexibility of multiple optical tracking methods, including full-spectrum active/passive hybrid optical tracking.1 It is the only guidance system with proprietary active technology and a non-invasive patient tracker, SpineMask. Image processing: Spine Guidance Software features completely redesigned applications, semi-automatic and automatic processing features, gesture recognition, and broad compatibility with various types of image sets. Spine Guidance Software: Spine Guidance Software is designed to help surgeons optimize their workflow, minimize their time in the OR and address complex clinical decisions and techniques intraoperatively. Its computational power is designed to support our spine product and software roadmap. It is our intention to develop and release new technologies within the Q ecosystem. “In my experience, Spine Guidance Software truly simplifies preoperative planning, navigation and execution,” said Stephen George, M.D., Director of Spine Surgery, Nicklaus Children's Hospital. “From what I have seen, the Q Guidance System is a powerful platform that has provided reliability and performance in a solution that is conveniently scalable to a wide array of surgical procedures, ranging from a single level fusion to a multi-level deformity correction. When used with the Airo TruCT scanner, Spine Guidance Software is designed to minimize time spent intraoperatively planning, thanks to its auto segmentation capability, while also allowing us the benefit of being able to image the patient in the surgical position. Its intuitive and customizable software enables us to configure the System to fit our preferences.” Stryker will be featuring the Q Guidance System and offering demonstrations at several upcoming meetings, including Society for Minimally Invasive Spine Surgery (SMISS) 2022 Annual Forum in Las Vegas, Sept. 29–Oct. 1, 2022 Congress of Neurological Surgeons (CNS) 2022 Annual Meeting in San Francisco, Oct. 8–12, 2022 North American Spine Society (NASS) Annual Meeting in Chicago, Oct. 12–15, 2022 About Stryker Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, and Orthopaedics and Spine that help improve patient and hospital outcomes. Alongside its customers around the world, Stryker impacts more than 100 million patients annually.

Read More